Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / TAK - Why The Misunderstood Pfizer Deal Makes Myovant A Great Low-Risk Investment

TAK - Why The Misunderstood Pfizer Deal Makes Myovant A Great Low-Risk Investment

Takeda Pharmaceutical Company Limited American Depositary Shares
  • The FDA is currently reviewing the relugolix combination therapy for symptoms of Uterine Fibroids and set a PDUFA date on 6/1/2021.
  • Myovant is currently successfully launching its first approved product ORGOVYX in partnership with Pfizer.
  • Relugolix has the potential to become the SoC in advanced prostate cancer, uterine fibroids, and endometriosis.
  • In the long term, Myovant aims to become a relevant player in the field of women's health or oncology.

For further details see:

Why The Misunderstood Pfizer Deal Makes Myovant A Great Low-Risk Investment
Stock Information
Company Name: Takeda Pharmaceutical Company Limited American Depositary Shares
Stock Symbol: TAK
Market: NYSE
Website: takeda.com
Menu
TAK TAK Quote TAK Short TAK News TAK Articles TAK Message Board
Get TAK Alerts

News, Short Squeeze, Breakout and More Instantly...